Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Quantum Genomics (MLQG)

  Print      Mail a friend

Friday 13 April, 2012

Quantum Genomics

Quantum Genomics announces initiation of a Firs...

Quantum Genomics announces initiation of a First-in-Human clinical study with QGC001, its lead compound for the treatment of hypertension
Massy, France -  April 13th 2012

Quantum Genomics (NYSE Euronext Paris : MLQGC), following the approval from the French Agency for Safety of Health Products (AFSSAPS),  announces today the initiation of a phase I clinical study in healthy volunteers with its product QGC001. QGC001 is the first of a new class of drugs that is able to monitor high blood pressure by inhibiting the aminopeptidase A enzyme (APA) at the brain level.

Arterial hypertension affects an estimated 1 billion people worldwide (13 million people in France). Despite the availability of many antihypertensive drugs, 30% to 60% of patients diagnosed with hypertension do not have their blood pressure properly controlled by current medications for various reasons (49% in France ([1])). Moreover, the overall incidence of resistant hypertension to at least three antihypertensive drugs (including a diuretic) is estimatedaround 8% to 12% of the hypertensive population.

Lionel Segard, CEO of Quantum Genomics says: "This first study in Human is a major milestone for our Company and demonstrates its ability to develop an innovative compound originated from academic research. QGC001 is the first representative of a new class of antihypertensive drugs that may improve the control of blood pressure in many patients with no current appropriate drug treatment and reduce their concomitant risks of cardiovascular diseases".

APA inhibitors, amongst which QGC001 is the first to reach the clinical stage, were co-discovered by the research teams of Dr. C. Llorens-Cortes (INSERM U1050/Collège of France) and Prof. BP. Roques (INSERM U1022/CNRS/Université Paris Descartes). "QGC001 has already demonstrated its efficacy after oral administration in several experimental models of hypertension. Its mechanism of action allows it to act simultaneously on the vessels, the heart, the elimination of water and salt in the urine. QGC001 might thus be useful for all patients suffering from hypertension, particularly those with a low renin profile whose high blood pressure is often more difficult to control with conventional blockers of the renin angiotensin system", comments Dr. Catherine Llorens-Cortes.
This First-in-Human clinical trial is a single ascending oral dose, double-blind and placebo-controlled Phase I study. "The trial will aim at assessing the overall safety, tolerability and pharmacokinetics of QGC001 in healthy volunteers" adds Fabrice Balavoine (Vice-President Research & Development).

The trial received financial support from the French National Agency for Research (ANR BiotecS). It is conducted in partnership with the Center for Clinical Investigation 9201/APHP-INSERM led by Pr. Michel Azizi (Hôpital Européen Georges Pompidou - Paris, France).

About QGC001

The objective of QGC001 is to offer a therapeutic alternative for the treatment of high blood pressure for all hypertensive patients particularly those with Low Renin High Vasopressin profile (LRHV).

The LRHV patients could represent 30% of hypertensive population and have reduced response to angiotensin I converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), renin inhibitors and beta-blockers.

About Quantum Genomics

QGC is a biopharmaceutical company that develops new therapies in areas where an unmet medical need exists.

QGC is presently focused on cardiovascular diseases and especially on arterial hypertension.

The company is co-developing its products with academic teams and will build strategic alliances with industrial partners to bring them to patients.

The company is based in Massy (France).

The CEO, Lionel Segard, is supported by an experienced management team including Fabrice Balavoine (VP Research & Development) and Michel Lepers (VP Business Development).

For more info see:
[1] Thobie H et al. BEH 2008;49-50: 478

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Quantum Genomics via Thomson Reuters ONE


a d v e r t i s e m e n t